Management tracks: Omeros, EdiGene

Omeros Corp. (NASDAQ:OMER) hired Eckhard Leifke as CMO and VP of clinical development. He was global project head/VP of early project and external opportunities - cardiovascular and metabolism and global head/VP of late-stage development diabetes at Sanofi (Euronext:SAN; NYSE:SNY). Leifke takes over oversight of clinical science and operations, medical affairs and pharmacovigilance from J. Steven Whitaker, who will now lead development of OMS721. The human mAb against mannan binding lectin serine peptidase 2 (MASP2) is in Phase III testing for thrombotic microangiopathies.

Gene editing company EdiGene Inc. (Beijing, China) hired Dong Wei as CEO. He was COO at Treos Bio Ltd. (London, U.K.). Wei is also a veteran of Shire plc (LSE:SHP; NASDAQ:SHPG), Johnson & Johnson (NYSE:JNJ) and BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN)...